Acetazolamide: adverse event reports filed with FDA

2,567

reports as suspect product

0% of all reports · about 115 a year

259

reports, 12 months to June 2026

346 in the 12 months before

87.3%

marked serious by the reporter

40.1% across the class

7%

record death among outcomes, as reported

179 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Acetazolamide reports recording the termmedian drug in carbonic anhydrase inhibitor

1. Drug ineffectivethe medicine did not work as expected18.8%482
2. Off label useused for a purpose or in a way not on the label16%412
3. Metabolic acidosistoo much acid in the body fluids7.3%188
4. Condition aggravatedthe condition being treated got worse6.9%176
5. Drug ineffective for unapproved indication4%103
6. Product use in unapproved indicationused for a purpose not on the label4%102
7. Dyspnoeashortness of breath3.6%92
8. Drug interactionan interaction between medicines3.5%89
9. Paraesthesiatingling or pins and needles3.4%87
10. Hypokalaemialow blood potassium3.3%84
11. Acute kidney injurysudden loss of kidney function2.9%75
12. Intraocular pressure increasedraised pressure in the eye2.8%72
13. Headachehead pain2.7%69
14. Choroidal effusion2.6%66
15. Foetal exposure during pregnancythe unborn baby was exposed to the medicine2.6%66
16. Somnolencedrowsiness2.5%64
17. Angle closure glaucoma2.4%62
18. Nauseafeeling sick2.4%62
19. Fatiguetiredness2.3%58
20. Toxicity to various agentspoisoning or toxic effect of one or more substances2.2%56
21. Vomitingbeing sick2%52
22. Dizzinesslight-headedness or unsteadiness1.9%50
23. Anxietyanxiety1.9%49
24. Therapy non-responderthe treatment did not work1.9%48
25. Choroidal detachment1.8%46
26. Drug intolerancethe medicine was not tolerated1.8%45
27. Lung disordera lung problem, type not specified1.8%45
28. Therapeutic product effect incomplete1.8%45
29. Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement1.6%42
30. Drug hypersensitivityan allergic-type reaction to a medicine1.6%40

Top 30 of 553 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 12 drugs in the carbonic anhydrase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 19,384 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 49.2% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 2,567 reports.

Drugs most often listed in the same reports

Other products listed in reports where Acetazolamide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the carbonic anhydrase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Acetazolamide as a suspect or interacting product; reports listing it only as a concomitant medication (3,412) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.